CN109965290A - Improve intestinal flora meal replacement powder and its application - Google Patents
Improve intestinal flora meal replacement powder and its application Download PDFInfo
- Publication number
- CN109965290A CN109965290A CN201711447314.6A CN201711447314A CN109965290A CN 109965290 A CN109965290 A CN 109965290A CN 201711447314 A CN201711447314 A CN 201711447314A CN 109965290 A CN109965290 A CN 109965290A
- Authority
- CN
- China
- Prior art keywords
- parts
- weight
- powder
- composition
- kudzu
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000843 powder Substances 0.000 title claims abstract description 101
- 230000000968 intestinal effect Effects 0.000 title abstract description 24
- 235000012054 meals Nutrition 0.000 title abstract description 19
- 235000007882 dietary composition Nutrition 0.000 claims abstract description 34
- 229920001202 Inulin Polymers 0.000 claims abstract description 29
- 244000302512 Momordica charantia Species 0.000 claims abstract description 29
- 235000009811 Momordica charantia Nutrition 0.000 claims abstract description 29
- 235000009812 Momordica cochinchinensis Nutrition 0.000 claims abstract description 29
- 235000018365 Momordica dioica Nutrition 0.000 claims abstract description 29
- 235000010575 Pueraria lobata Nutrition 0.000 claims abstract description 29
- 244000046146 Pueraria lobata Species 0.000 claims abstract description 29
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims abstract description 29
- 229940029339 inulin Drugs 0.000 claims abstract description 29
- 241000234435 Lilium Species 0.000 claims abstract description 25
- 235000013312 flour Nutrition 0.000 claims abstract description 23
- 206010012601 diabetes mellitus Diseases 0.000 claims abstract description 20
- 239000000203 mixture Substances 0.000 claims description 75
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 21
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 21
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 21
- 239000000811 xylitol Substances 0.000 claims description 21
- 229960002675 xylitol Drugs 0.000 claims description 21
- 235000010447 xylitol Nutrition 0.000 claims description 21
- 235000007354 Coix lacryma jobi Nutrition 0.000 claims description 6
- 244000077995 Coix lacryma jobi Species 0.000 claims description 6
- 244000005709 gut microbiome Species 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 5
- 230000002265 prevention Effects 0.000 claims description 2
- 235000007516 Chrysanthemum Nutrition 0.000 claims 1
- 244000189548 Chrysanthemum x morifolium Species 0.000 claims 1
- 235000013305 food Nutrition 0.000 abstract description 18
- 230000000694 effects Effects 0.000 abstract description 17
- 230000036541 health Effects 0.000 abstract description 11
- 244000005700 microbiome Species 0.000 abstract description 11
- 230000002218 hypoglycaemic effect Effects 0.000 abstract description 7
- 241000282414 Homo sapiens Species 0.000 abstract description 6
- 239000000463 material Substances 0.000 abstract description 6
- 239000002994 raw material Substances 0.000 abstract description 5
- 230000006872 improvement Effects 0.000 abstract description 4
- 231100000331 toxic Toxicity 0.000 abstract description 3
- 230000002588 toxic effect Effects 0.000 abstract description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 32
- 210000004369 blood Anatomy 0.000 description 32
- 239000008280 blood Substances 0.000 description 32
- 239000008103 glucose Substances 0.000 description 26
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 21
- 238000012360 testing method Methods 0.000 description 16
- 150000002632 lipids Chemical class 0.000 description 15
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
- 241000894006 Bacteria Species 0.000 description 11
- 241000589516 Pseudomonas Species 0.000 description 10
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 10
- 238000000034 method Methods 0.000 description 10
- 201000001421 hyperglycemia Diseases 0.000 description 9
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 9
- 241000606125 Bacteroides Species 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 102000004877 Insulin Human genes 0.000 description 7
- 108090001061 Insulin Proteins 0.000 description 7
- 241000266824 Oscillospira Species 0.000 description 7
- 230000007423 decrease Effects 0.000 description 7
- 229940125396 insulin Drugs 0.000 description 7
- 238000007410 oral glucose tolerance test Methods 0.000 description 7
- 230000000291 postprandial effect Effects 0.000 description 7
- 239000006041 probiotic Substances 0.000 description 7
- 235000018291 probiotics Nutrition 0.000 description 7
- 241000731710 Allobaculum Species 0.000 description 6
- 241001050506 Mucispirillum Species 0.000 description 6
- 230000009286 beneficial effect Effects 0.000 description 6
- 235000005911 diet Nutrition 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 241000785902 Odoribacter Species 0.000 description 5
- 235000012000 cholesterol Nutrition 0.000 description 5
- 210000002784 stomach Anatomy 0.000 description 5
- 150000003626 triacylglycerols Chemical class 0.000 description 5
- 241001202853 Blautia Species 0.000 description 4
- 108010007622 LDL Lipoproteins Proteins 0.000 description 4
- 102000007330 LDL Lipoproteins Human genes 0.000 description 4
- 208000008589 Obesity Diseases 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 230000037213 diet Effects 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 235000020824 obesity Nutrition 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 102100030797 Conserved oligomeric Golgi complex subunit 2 Human genes 0.000 description 3
- 206010012735 Diarrhoea Diseases 0.000 description 3
- 108010010234 HDL Lipoproteins Proteins 0.000 description 3
- 102000015779 HDL Lipoproteins Human genes 0.000 description 3
- 101000920113 Homo sapiens Conserved oligomeric Golgi complex subunit 2 Proteins 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 241000194017 Streptococcus Species 0.000 description 3
- 150000004283 biguanides Chemical class 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 230000001771 impaired effect Effects 0.000 description 3
- 210000000936 intestine Anatomy 0.000 description 3
- 230000002906 microbiologic effect Effects 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 229940123208 Biguanide Drugs 0.000 description 2
- 241000588807 Bordetella Species 0.000 description 2
- 206010018473 Glycosuria Diseases 0.000 description 2
- 108010023302 HDL Cholesterol Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 206010022489 Insulin Resistance Diseases 0.000 description 2
- 241000186660 Lactobacillus Species 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- 230000035622 drinking Effects 0.000 description 2
- 229940125532 enzyme inhibitor Drugs 0.000 description 2
- 239000002532 enzyme inhibitor Substances 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 235000008216 herbs Nutrition 0.000 description 2
- 230000003345 hyperglycaemic effect Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 229940039696 lactobacillus Drugs 0.000 description 2
- 108010022197 lipoprotein cholesterol Proteins 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- 235000013406 prebiotics Nutrition 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 241000605059 Bacteroidetes Species 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 108010015776 Glucose oxidase Proteins 0.000 description 1
- 239000004366 Glucose oxidase Substances 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010029164 Nephrotic syndrome Diseases 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 102000004139 alpha-Amylases Human genes 0.000 description 1
- 108090000637 alpha-Amylases Proteins 0.000 description 1
- 229940024171 alpha-amylase Drugs 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 235000021152 breakfast Nutrition 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 230000003031 feeding effect Effects 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002213 flavones Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 230000009246 food effect Effects 0.000 description 1
- 230000007160 gastrointestinal dysfunction Effects 0.000 description 1
- 229940116332 glucose oxidase Drugs 0.000 description 1
- 235000019420 glucose oxidase Nutrition 0.000 description 1
- 238000007446 glucose tolerance test Methods 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- VUZPPFZMUPKLLV-UHFFFAOYSA-N methane;hydrate Chemical compound C.O VUZPPFZMUPKLLV-UHFFFAOYSA-N 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 208000009928 nephrosis Diseases 0.000 description 1
- 231100001027 nephrosis Toxicity 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000000529 probiotic effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
- A23C9/154—Milk preparations; Milk powder or milk powder preparations containing additives containing thickening substances, eggs or cereal preparations; Milk gels
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
- A23C9/156—Flavoured milk preparations ; Addition of fruits, vegetables, sugars, sugar alcohols or sweeteners
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
- A23L19/01—Instant products; Powders; Flakes; Granules
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
- A23L19/10—Products from fruits or vegetables; Preparation or treatment thereof of tuberous or like starch containing root crops
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
- A23L33/22—Comminuted fibrous parts of plants, e.g. bagasse or pulp
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L7/00—Cereal-derived products; Malt products; Preparation or treatment thereof
- A23L7/10—Cereal-derived products
- A23L7/198—Dry unshaped finely divided cereal products, not provided for in groups A23L7/117 - A23L7/196 and A23L29/00, e.g. meal, flour, powder, dried cereal creams or extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/733—Fructosans, e.g. inulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/42—Cucurbitaceae (Cucumber family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/488—Pueraria (kudzu)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8967—Lilium, e.g. tiger lily or Easter lily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
- A61K36/8994—Coix (Job's tears)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Botany (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Molecular Biology (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a kind of improvement intestinal flora meal replacement powder and its applications.Dietary composition provided by the invention, including selected from least one of kudzu-vine root powder, lotus-seed-heart powder, lily root flour, inulin and balsam pear powder.This product can reach hypoglycemic effect, and raw material is all the common food materials having no toxic side effect, and meets day for human beings Chang Suoxu, and can achieve the purpose that health by the enteric microorganism of adjusting T2D diabetic population.
Description
Technical field
The invention belongs to field of health care products, it is related to a kind of improvement intestinal flora meal replacement powder and its application.
Background technique
It has lived away from home in human body intestinal canal a large amount of symbiotic microorganism, these symbiotic microorganism groups constitute " the second of human body
Organ " not only cooperates with host to participate in the digestion and absorption of nutriment, but also plays important work to the maintenance of human health
With.For cell quantity, the quantity of all cells of enteric microorganism is 10 times of number of human body cell quantity, these are huge micro-
Biocenose mainly has species composition to be: Firmicutes and Bacteroidetes two major classes.More and more researches show that the micro- life of enteron aisle
The composition and diversity of object have close relationship with a variety of diseases, for example, obesity, diabetes, irritable bowel syndrome,
Ulcerative enteritis, colon cancer, fatty liver etc..Since environment, diet, drug etc. influence, the intestines under original health status are broken
The balance of road microorganism leads to function of intestinal canal disorder, and then induces the generation of above several diseases.
In recent years, with the raising of people's daily life level, dietary structure is gradually unbalance, the metabolism such as obesity, diabetes
The disease incidence of property disease increases rapidly.According to the statistics of the World Health Organization, there are about 4.22 hundred million people to suffer from diabetes for the whole world in 2014, cuts
Only 2012, because The dead quantity caused by diabetes reaches 1,500,000 people.Therefore, diabetes, which become, works as next great public affairs
Health problem altogether.Diabetes are a kind of diseases that the pathoglycemia as caused by many factors is excessively high, mainly due to insulin point
Metabolic disorder caused by insufficient or insulin function defect is secreted, the pathogenetic common high risk factor of glycosuria is caused to have something lost
Biography factor, environmental factor and undesirable living habit.Diabetes occur can along with the appearance of many complication, for example,
And premature coronary heart disease, hypertension, myocardial infarction, cerebral apoplexy, senile dementia, Parkinson, nephrosis, retinopathy etc., serious drop
The quality of life of low patient.Wherein type-II diabetes are a kind of non-insulin-dependent diabetes mellitus, and number of patients accounts for all glycosurias
The 90% of the patient populations of disease.A large number of studies show that the morbidity of type-II diabetes and the disorder of intestinal flora have close connection
System, intestinal flora adjusts energy balance between host and inflammatory reaction have it is close contact, the morbidity of type-II diabetes
Mainly caused by insulin resistance and low-level inflammatory reaction.
Hypoglycemic medicine currently used for treating diabetes has sulphonyl urea class, alpha-gluconase activity enzyme inhibitor and biguanides,
Wherein sulphonyl urea class is chiefly to facilitate insulin secretion, but can cause serious liver, injury of kidney, and allergic constitution should not take
With；Alpha-gluconase activity enzyme inhibitor is mainly to pass through the activity for inhibiting alpha-amylase and enteral alpha-gluconase activity enzyme, inhibits carbon water
The hydrolysis of compound to achieve the purpose that reduce postprandial blood sugar, but is easy to cause abdominal distension, the adverse reactions such as diarrhea；Biguanides
Class drug can reach hypoglycemic purpose by adjusting blood glucose transhipment, for example delay sugar absorption, the decomposition of promotion glucose, inhibit liver
Dirty glucose generates, and increases suction pressure protein content.Biguanides also bring along some side effects, easily cause intestines
Stomach upset, diarrhea, vomiting, fash, long-term use are easy to appear inactivation.
Summary of the invention
The object of the present invention is to provide a kind of improvement intestinal flora meal replacement powder and its applications.
Dietary composition provided by the invention, including in kudzu-vine root powder, lotus-seed-heart powder, lily root flour, inulin and balsam pear powder
It is at least one.
Above-mentioned dietary composition can also be made of kudzu-vine root powder, lotus-seed-heart powder, lily root flour, inulin and balsam pear powder.
In the dietary composition, the parts by weight of each component are as follows:
1~40 part of kudzu-vine root powder, 10~60 parts of lotus-seed-heart powder, 2~40 parts of lily root flour, 10~50 parts of inulin, balsam pear powder 2~40
Part.
It may also include xylitol and oatmeal in the dietary composition.
The dietary composition can also be only by xylitol, oatmeal, kudzu-vine root powder, lotus-seed-heart powder, lily root flour, inulin and balsam pear powder
Composition.
In the dietary composition, the parts by weight of each component are as follows:
2~40 parts of xylitol, 2~50 parts of oatmeal, 1~40 part of kudzu-vine root powder, 10~60 parts of lotus-seed-heart powder, lily root flour 2~40
Part, 10~50 parts of inulin, 2~40 parts of balsam pear powder.
The oatmeal, kudzu-vine root powder, lotus-seed-heart powder, lily root flour, inulin and balsam pear powder mesh number be 50-200 mesh, specially
80 mesh.
The dietary composition is any one of following composition a into composition c:
The composition a is grouped as by the group of following each parts by weight:
Xylitol 10-20 parts by weight, oatmeal 12-50 parts by weight, kudzu-vine root powder 6-30 parts by weight, lotus-seed-heart powder 28-33 weight
Part, lily root flour 10-20 parts by weight, 24 parts by weight of inulin, balsam pear powder 10-20 parts by weight；
The composition b is grouped as by the group of following each parts by weight:
Xylitol 10-25 parts by weight, oatmeal 12-42 parts by weight, kudzu-vine root powder 6-24 parts by weight, lotus-seed-heart powder 28-38 weight
Part, lily root flour 10-25 parts by weight, 24 parts by weight of inulin, balsam pear powder 10-25 parts by weight；
The composition c is grouped as by the group of following each parts by weight:
Xylitol 20-25 parts by weight, oatmeal 42-50 parts by weight, kudzu-vine root powder 24-30 parts by weight, lotus-seed-heart powder 33-38 weight
Part, lily root flour 20-25 parts by weight, 24 parts by weight of inulin, balsam pear powder 20-25 parts by weight.
Specifically, the dietary composition is any one of following composition d into composition f:
The composition d is grouped as by the group of following each parts by weight:
10 parts by weight of xylitol, 12 parts by weight of oatmeal, 6 parts by weight of kudzu-vine root powder, 28 parts by weight of lotus-seed-heart powder, 10 weight of lily root flour
Measure part, 24 parts by weight of inulin, 10 parts by weight of balsam pear powder；
The composition e is grouped as by the group of following each parts by weight:
20 parts by weight of xylitol, 50 parts by weight of oatmeal, 30 parts by weight of kudzu-vine root powder, 33 parts by weight of lotus-seed-heart powder, lily root flour 20
Parts by weight, 24 parts by weight of inulin, 20 parts by weight of balsam pear powder；
The composition f is grouped as by the group of following each parts by weight:
25 parts by weight of xylitol, 42 parts by weight of oatmeal, 24 parts by weight of kudzu-vine root powder, 38 parts by weight of lotus-seed-heart powder, lily root flour 25
Parts by weight, 24 parts by weight of inulin, 25 parts by weight of balsam pear powder.
In addition, aforementioned present invention provide dietary composition preparation improve intestinal microflora product in application and
Application of the dietary composition in the product of preparation prevention and/or treatment diabetes, also belongs to protection scope of the present invention.Its
In, the product can be meal replacement powder or dairy products.The improvement intestinal microflora, which concretely increases, is beneficial to blood pressure and blood lipoid tune
The content of the Pseudomonas probiotics of section increases the abundance of core flora, reduces the bacterial content that causes a disease.Wherein, described to be beneficial to blood glucose blood
Pseudomonas probiotics concretely genus lactubacillus (Latobacilus), Bacteroides (Bacteroides) and the labor Te Shi that rouge is adjusted
The probiotics of Pseudomonas (Blautia)；
The core flora is specially Allobaculum flora and Oscillospira flora, both floras be
Primordial growth traits occupy the flora of advantage, and Oscillospira is related with fat generation is reduced；
The pathogenic bacteria concretely Mucispirillum, Odoribacter, Pseudomonas and
At least one of Streptococcus；Mucispirillum inhibits colonic mucosa, destroys gut barrier；Odoribacter
It is distributed in large intestine cancerous swelling more；Pseudomonas is endogenous inflammatory flora.
In dietary composition provided by the invention, containing in a variety of integration of drinking and medicinal herbs such as pueraria lobata, adlay, lily, inulin, balsam pear
Medicinal material is rich in flavones, polysaccharide component.This composition can significantly improve insulin impaired and the people's of diabetes early stage
Fasting blood-glucose and postprandial blood sugar.And it can increase genus lactubacillus (Latobacilus), Bacteroides (Bacteroides) He Laote
Bordetella (Blautia) etc. is beneficial to the content of the Pseudomonas probiotics of blood pressure and blood lipoid adjusting, increases the abundance of core flora
(Allobaculum and Oscillospira), reduction Mucispirillum, Odoribacter, Pseudomonas,
The pathogenic bacterial content such as Streptococcus.The present invention will be hypoglycemic food materials and combination of prebiotics, combine the function of food materials
It is the effect of effect and enteric microorganism, common to play the effect for adjusting the balance of body glycometabolism, it is not only able to that blood glucose is effectively reduced,
It avoids general blood glucose-control drug and easily leads to the side effects such as hypoglycemia, blood glucose fluctuation be too fast, and adjust the flat of intestinal flora
Weighing apparatus can promote health comprehensively, be suitable for being used for a long time.
The beneficial effects of the present invention are: the present invention provides a kind of dietary composition preparation adjust beneficial bacteria of intestinal tract with
Purposes in the food of harmful bacteria.Inventor observes the combination by high lipid food inducing mouse obesity type-II diabetes model
Object passes through influence of the intestinal flora to mouse lipid metaboli, in accordance with the present invention it has now surprisingly been found that, dietary composition of the present invention can be adjusted
The enteric flora disturbance as caused by diet can significantly modify the composition of intestinal flora, tend to intestinal flora unbalance in vivo just
Often, the blood lipid and blood glucose target of the obesity and then caused by adjusting enteric flora disturbance by caused by diet, can obviously reduce blood
The content of total cholesterol, can reduce cholesterol, low-density lipoprotein content in clear.Pass through the research of metagenomics, discovery
The composition can be improved the abundance for being enriched in probiotics in Healthy People intestinal flora, and can reduce and be enriched in fat and pancreas islet
The abundance of harmful bacteria in the patient that element is resisted.
According to an embodiment of the invention, the ingredient in the composition and the composition, adjust enteric microorganism and
The function and effect for adjusting the working composition of blood glucose are better than single component.
The ingredient of composition in the present invention, all raw materials both are from the food in integration of drinking and medicinal herbs, derived from natural.And it is free of
It with chemicals, has no toxic side effect, securely and reliably.Material source can be easy to get extensively, and component passes through scientific compatibility, curative effect
Significantly, there is collaboration accretion.Manufacture craft is simple, and storage and application are safe, is easily esthetically acceptable to the consumers.
The present invention realizes safety by the scientific compatibility to pure natural edible raw material, significant hypoglycemic, control drink
The effect of food.Blood glucose is adjusted for people, and new selection is provided.
This product can reach hypoglycemic effect, and raw material by the enteric microorganism of adjusting T2D diabetic population
All it is the common food materials having no toxic side effect, meets day for human beings Chang Suoxu, and can achieve the purpose that health.It is new studies have shown that very
More diseases, inferior health are all as caused by intestinal microflora disorder.The equilibrium state of enteric bacteria group is strong for body
Health has great significance, and some bad habits in living, then can upset enteron aisle " the peaceful world ": 1. chronic dietaries are not
It is balanced.Such as excessively take in meat or vegetables, eat unhealthy food for a long time etc..2. taking in the food being contaminated by bacterial.Reduction is supported
Drag makes conditioned pathogen " degenerating ", or intake harmful bacteria is excessive, and intestinal flora is unbalance, symptom of diarrhea occurs.3. the age increases
It is long.Increase with the age, part beneficial bacterium is reduced, harmful bacteria increases, and body immunity weakens.4. using some drugs.Excessive clothes
Cause intestinal flora unbalance with antibiotic, immunity degradation.5. gastrointestinal dysfunction.Organic reason causes intestinal flora to lose
Weighing apparatus, immunity also decline.6, the factors such as constipation.Excrement residence time in enteron aisle is too long, can restrict the growth of certain bacteriums, make
It lacks of proper care at the living environment of flora.Inherently a kind of metabolic disease of type-II diabetes, insulin is impaired and diabetes
Early stage can be controlled by regulating and controlling diet.This product be not achieved the purpose that by the common product of taking medicine control blood glucose, and
It is to match effect by the 5 of composition, reaches the intestinal flora for adjusting the disorder of T2D diabetes patient, enrich T2D diabetes patient's
Prebiotic bacterium amount, adjusts the purpose of blood glucose, therefore has boundless prospect.
Detailed description of the invention
Fig. 1 is the influence of embodiment 1 (composition 1) to hyperglycemia mouse intestinal flora structure.
Fig. 2 is the influence of embodiment 2 (composition 2) to hyperglycemia mouse intestinal flora structure.
Fig. 3 is the influence of embodiment 3 (composition 3) to hyperglycemia mouse intestinal flora structure.
Fig. 4 is influence of 3 meal replacement powder of composition to hyperglycemia population intestinal microflora.
Specific embodiment
The present invention is further elaborated combined with specific embodiments below, but the present invention is not limited to following embodiments.Institute
State method is conventional method unless otherwise instructed.The raw material can obtain unless otherwise instructed from public commercial source.
In following embodiments, inulin used is purchased from the three lives cool Bioisystech Co., Ltd；Adlay used is limited purchased from one side's pharmacy of Guangdong
Company.
Embodiment 1
Composition 1: 10 parts by weight of xylitol, 12 parts by weight of oat, 6 parts by weight of pueraria lobata, 28 parts by weight of adlay, lily are weighed
10 parts by weight, 24 parts by weight of inulin, 10 parts by weight of balsam pear powder, smash it through 80 meshes respectively, are uniformly mixed, obtain the present invention and mention
The dietary composition of confession.
Embodiment 2
Composition 2: 20 parts by weight of xylitol, 50 parts by weight of oat, 30 parts by weight of pueraria lobata, 33 parts by weight of adlay, hundred are weighed
20 parts by weight, 24 parts by weight of inulin, 20 parts by weight of balsam pear powder are closed, smash it through 80 meshes respectively, is uniformly mixed, obtains the present invention
The dietary composition of offer.
Embodiment 3
Composition 3: 25 parts by weight of xylitol, 42 parts by weight of oat, 24 parts by weight of pueraria lobata, 38 parts by weight of adlay, hundred are weighed
25 parts by weight, 24 parts by weight of inulin, 25 parts by weight of balsam pear powder are closed, smash it through 80 meshes respectively, is uniformly mixed, obtains the present invention
The dietary composition of offer.
Embodiment 4, zoopery reduce blood glucose
Auxiliary hyperglycemic function animal according to Ministry of Public Health's " health food is examined and assessment technique specification (2003) " is real
Evaluation method is tested, the composition prepared in embodiment 1 is evaluated, concrete operations are as follows:
1 test method
The present embodiment feeds induction using high lipid food and causes insulin resistance and Type 2 Diabetic (T2D) model small
Mouse is treated 2 months by edible meal replacement powder, investigates 3 kinds of meal replacement powder combinations in embodiment 1,2,3 and controls diabetes B (T2D)
Therapeutic effect.
1, the modeling of T2D mouse: test mice use C57bL/6 mouse, 8 week old, every group mouse 8, mouse test
Environment is SPF grades, is grouped modeling within adaptable fed 1 week.The method that modeling method uses induction high in fat, fasting blood sugar,
And insulin resistant experiment compared with control group mice notable difference can be used as insulin be damaged and diabetes early stage mould
Type mouse.
2, experimental group:
(1) model (model) group: the mouse of T2D model carries out stomach-filling using physiological saline；
(2) mouse of composition 1:T2D model is controlled using the method that composition 1 in embodiment 1 replaces 10% high lipid food
It treats；
(3) mouse of composition 2:T2D model replaces 10% high lipid food using 2 meal replacement powder of composition in embodiment 2
Method treatment.
(4) mouse of composition 3:T2D model, the method that 3 meal replacement powder of composition replaces 10% high lipid food in embodiment 3
Treatment.
3 test processes
Preparatory work of experiment:
The additive amount for determining composition 1,2,3 in mouse feed closes meal replacement powder and high lipid food in mouse feed company
At mouse chow.
Experimentation:
It is tested according to grouping situation, for T2D at starting to be treated after mould, treatment continues 2 months.Every day entry mouse
Feeding activities situation, and weigh in, carry out tail vein blood every 2 weeks, detect the fasting blood sugar of mouse, in treatment the 4th
Week and experiment measure the glucose tolerance (OGTT) of mouse when terminating.Test put to death mouse after 2 months, and all mouse pluck eyeball
Take blood, de- neck, total cholesterol (TC) in detection serum, triglycerides (TG), high-density lipoprotein cholesterol (HDL-C) and low close
It spends lipoprotein cholesterol (LDL-C).
4 test results
Changes of weight
As shown in table 1, it is induced by 8 weeks high lipid foods, the model group of high lipid food induction, 1 group of composition, composition
2 groups, 3 groups of mouse weights of composition increase.After 8 weeks, Clinical intervention is carried out to mouse.After treating 8 weeks, composition 1,2,3
Group is declined compared to model group body weight.
Table 1, mouse weight variation
| Packet numbering | 0 week | Modeling 4 weeks | Modeling 8 weeks | Intervene 4 weeks | Intervene 8 weeks |
| Model group (g) | 22.48 | 27.99 | 32.42 | 36.87 | 40.24 |
| 1 group of composition (g) | 21.56 | 27.76 | 32.59 | 34.12 | 36.76 |
| 2 groups of composition (g) | 21.54 | 28.42 | 33.23 | 35.25 | 38.45 |
| 3 groups of composition (g) | 21.67 | 28.23 | 32.76 | 32.35 | 32.79 |
Fasting blood-glucose and OGTT result
It as shown in table 2, table 3, is induced by 8 weeks high lipid foods, 1 group of composition, the composition 2 of high lipid food induction
The OGTT area under the curve (AUC) and model that group, 3 groups of composition of mouse fasting blood-glucose and OGTT Glucose Tolerance Test measure
Group is compared, and has apparent difference (P < 0.05).By 8 weeks meal replacement powder Clinical interventions, composition compared model group, on an empty stomach
Blood glucose is declined, and obvious (P < 0.05) is declined.OGTT test, composition compare model group, and OGTT area under the curve (AUC) has
Apparent decline, significant difference (P < 0.05), wherein 3 groups of composition of difference is most obvious.
Table 2, the variation of mouse fasting blood-glucose
Table 3, mouse OGTT test result
Lipids detection result
It after experiment, is detected by blood lipid of the serum to mouse, including total cholesterol (TC), triglycerides
(TG), low-density lipoprotein (LDLC) and high-density lipoprotein (HDLC), testing result is as shown in table 4 to be compared with model group, group
It closes 1 group of object total liver sterol TC and low-density lipoprotein LDLC to significantly decrease, and significant difference (P < 0.05).Triglyceride has
Declined, difference is not significant.High-density lipoprotein has certain rising at 1 group of composition, and difference is not significant.It is sweet in composition 3
Oily three esters, total cholesterol and low-density lipoprotein all decline significantly, and high-density lipoprotein difference is not significant.
Lipids detection result in table 4, mice serum
| Packet numbering | TC(mmol/L) | TG(mmol/L) | LDLC(mmol/L) | HDLC(mmol/L) |
| Model group | 6.82 | 1.74 | 2.45 | 2.76 |
| 1 group of composition | 5.38* | 1.03 | 1.65* | 3.16 |
| 2 groups of composition | 6.24 | 1.69 | 2.47 | 2.48 |
| 3 groups of composition | 3.56* | 0.68* | 1.04* | 4.58 |
Enteric microorganism testing result
Table 5, composition 1 are to the data (unit: relative abundance %) of hyperglycemia mouse intestinal microbiological effect
Table 6, composition 2 are to the data (unit: relative abundance %) of hyperglycemia mouse intestinal microbiological effect
| Model group | 2 groups of composition | |
| Lactobacillus | 2.53 | 14.08 |
| Allobaculum | 19.53 | 18.15 |
| Oscillospira | 17.73 | 13.62 |
| Mucispirillum | 6.07 | 4.08 |
| Blautia | 2.20 | 4.08 |
| Bacteroides | 2.27 | 0.85 |
Table 7, composition 3 are to the data (unit: relative abundance %) of hyperglycemia mouse intestinal microbiological effect
| Model group | 3 groups of composition | |
| Allobaculum | 7.55 | 8.85 |
| Oscillospira | 4.85 | 14.56 |
| Lactobacillus | 1.00 | 1.33 |
| Bacteroides | 1.14 | 2.44 |
| Rikennella | 0.87 | 2.89 |
| Pseudomonas | 3.00 | 1.11 |
| Odoribacter | 2.29 | 0.00 |
1,2,3 resulting composition 1,2,3 of embodiment is respectively to hyperglycemia mouse model intestines in Fig. 1-Fig. 3 respectively present invention
The adjusted result of road Bacterial community.
It can be seen that composition can significantly improve probiotics (genus lactubacillus (Latobacilus) Bacteroides
(Bacteroides), labor spy Bordetella (Blautia) etc.) abundance, inhibit harmful bacteria (Mucispirillum,
Odoribacter, Pseudomonas, Streptococcus etc.), and increase or maintain health population dominant bacteria
The content of Allobaculum and Oscillospira.
Embodiment 5, crowd's experiment results
1 test method
Select 80 insulin impaired by the principle of voluntariness or the type II diabetes people of early detection, wherein 50 people of male,
30 people of women, between the range of age 45-55 one full year of life.Without complication such as liver kidneys, contrast design after taking in front of test-meal
Volunteer is divided into 2 groups, and the normal diet of diabetic carries out before experimental group group breakfast and lunch, avoids height high in fat
Confectionery object.Dinner uniformly eats the meal replacement powder 50g of composition 3 in embodiment 3, eats after being brewed with boiled water.Control group is according to it
Preceding eating habit, dinner do not eat meal replacement powder.Continuously take 30 days.The variation of patient's blood pressure, stool and urine, weight is monitored, and
Measurement empty stomach and postprandial 2 hours blood glucose (using glucose oxidase method).
2 test judgment criteria
Effective: cardinal symptom disappears, and on an empty stomach or postprandial 2 hours blood glucose relatively treats preceding decline and is no more than 30.0%.
Effective: cardinal symptom is obviously improved, and decline is no more than 10.0% before relatively treating with postprandial 2 hours blood glucose on an empty stomach.
Invalid: cardinal symptom is not improved, and is dropped by less than 10.0% before relatively treating with postprandial 2 hours blood glucose on an empty stomach.
3 test results
Foretaste crowd's blood glucose test results
Table 8 foretastes crowd's blood glucose test results
As can be seen from Table 8, after crowd's experiment, the decline of experimental group fasting blood-glucose is obvious, and significant effect, rate of descent reaches
To 29.3%.The rate of descent of postprandial blood sugar reaches 23.17%.Control group test front and back does not have significant change.It can be seen that this hair
Bright meal replacement powder has the function of apparent Hyperglycemic health care, and to tested by improving intestinal microflora to reduce blood glucose
The harmless effect of population health, i.e., meal replacement powder composition of the invention have significant antidiabetic function.
Crowd tests enteric microorganism testing result and sees Fig. 4 and table 9, takes meal replacement powder as seen from the figure, can significantly mention
High probiotic lactic acid Pseudomonas (Latobacilus) content reduces harmful bacteria Mucispirillum.And increase or maintain healthy group
The content of body dominant bacteria Allobaculum and Oscillospira.
The influence data of table 9,3 meal replacement powder of composition to hyperglycemia population enteric microorganism
Claims (10)
1. a kind of dietary composition, including selected from least one of kudzu-vine root powder, lotus-seed-heart powder, lily root flour, inulin and balsam pear powder.
2. dietary composition according to claim 1, it is characterised in that: the dietary composition by kudzu-vine root powder, lotus-seed-heart powder,
Lily root flour, inulin and balsam pear powder composition.
3. dietary composition according to claim 2, it is characterised in that: in the dietary composition, the weight of each component
Part is as follows:
1~40 part of kudzu-vine root powder, 10~60 parts of lotus-seed-heart powder, 2~40 parts of lily root flour, 10~50 parts of inulin, 2~40 parts of balsam pear powder.
4. dietary composition according to claim 1 to 3, it is characterised in that: further include in the dietary composition
Xylitol and oatmeal.
5. dietary composition according to claim 1 or 4, it is characterised in that: the dietary composition is by xylitol, oat
Powder, kudzu-vine root powder, lotus-seed-heart powder, lily root flour, inulin and balsam pear powder composition.
6. dietary composition according to claim 1 or 4 or 5, it is characterised in that: in the dietary composition, each component
Parts by weight it is as follows:
2~40 parts of xylitol, 2~50 parts of oatmeal, 1~40 part of kudzu-vine root powder, 10~60 parts of lotus-seed-heart powder, 2~40 parts of lily root flour, chrysanthemum
10~50 parts of powder, 2~40 parts of balsam pear powder.
7. any dietary composition in -6 according to claim 1, it is characterised in that: the oatmeal, kudzu-vine root powder, adlay
Powder, lily root flour, inulin and balsam pear powder mesh number be 50-200 mesh, specially 80 mesh.
8. any dietary composition in -7 according to claim 1, it is characterised in that: the dietary composition is such as the following group
Close any one of object a into composition c:
The composition a is grouped as by the group of following each parts by weight:
Xylitol 10-20 parts by weight, oatmeal 12-50 parts by weight, kudzu-vine root powder 6-30 parts by weight, lotus-seed-heart powder 28-33 parts by weight, hundred
Close powder 10-20 parts by weight, 24 parts by weight of inulin, balsam pear powder 10-20 parts by weight；
The composition b is grouped as by the group of following each parts by weight:
Xylitol 10-25 parts by weight, oatmeal 12-42 parts by weight, kudzu-vine root powder 6-24 parts by weight, lotus-seed-heart powder 28-38 parts by weight, hundred
Close powder 10-25 parts by weight, 24 parts by weight of inulin, balsam pear powder 10-25 parts by weight；
The composition c is grouped as by the group of following each parts by weight:
Xylitol 20-25 parts by weight, oatmeal 42-50 parts by weight, kudzu-vine root powder 24-30 parts by weight, lotus-seed-heart powder 33-38 parts by weight,
Lily root flour 20-25 parts by weight, 24 parts by weight of inulin, balsam pear powder 20-25 parts by weight.
Specifically, the dietary composition is any one of following composition d into composition f:
The composition d is grouped as by the group of following each parts by weight:
10 parts by weight of xylitol, 12 parts by weight of oatmeal, 6 parts by weight of kudzu-vine root powder, 28 parts by weight of lotus-seed-heart powder, 10 weight of lily root flour
Part, 24 parts by weight of inulin, 10 parts by weight of balsam pear powder；
The composition e is grouped as by the group of following each parts by weight:
20 parts by weight of xylitol, 50 parts by weight of oatmeal, 30 parts by weight of kudzu-vine root powder, 33 parts by weight of lotus-seed-heart powder, 20 weight of lily root flour
Part, 24 parts by weight of inulin, 20 parts by weight of balsam pear powder；
The composition f is grouped as by the group of following each parts by weight:
25 parts by weight of xylitol, 42 parts by weight of oatmeal, 24 parts by weight of kudzu-vine root powder, 38 parts by weight of lotus-seed-heart powder, 25 weight of lily root flour
Part, 24 parts by weight of inulin, 25 parts by weight of balsam pear powder.
9. application of any dietary composition in the product that preparation improves intestinal microflora in claim 1-8.
10. any dietary composition answering in the product of preparation prevention and/or treatment diabetes in claim 1-8
With.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711447314.6A CN109965290B (en) | 2017-12-27 | 2017-12-27 | Meal replacement powder for improving intestinal flora and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711447314.6A CN109965290B (en) | 2017-12-27 | 2017-12-27 | Meal replacement powder for improving intestinal flora and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN109965290A true CN109965290A (en) | 2019-07-05 |
| CN109965290B CN109965290B (en) | 2023-06-20 |
Family
ID=67071164
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201711447314.6A Active CN109965290B (en) | 2017-12-27 | 2017-12-27 | Meal replacement powder for improving intestinal flora and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109965290B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111213877A (en) * | 2020-01-21 | 2020-06-02 | 天津天福康生物科技有限公司 | Meal replacement powder with function of regulating organism metabolism and preparation method thereof |
| CN112841533A (en) * | 2021-02-01 | 2021-05-28 | 四川斯力健农业科技有限公司 | Weight-losing meal replacement composition and preparation method thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1545943A (en) * | 2003-11-28 | 2004-11-17 | 南宁领标生物技术有限责任公司 | Processing technique for compound product of kudzu root and bitter gourd |
| CN102697060A (en) * | 2012-05-23 | 2012-10-03 | 广东省农业科学院农业生物技术研究所 | Bitter-gourd nutritious food with auxiliary hypoglycemic effect and preparation method thereof |
| CN103830496A (en) * | 2014-02-28 | 2014-06-04 | 廊坊市思科农业技术有限公司 | Blood glucose reduction resistant composition |
| CN104585746A (en) * | 2014-12-23 | 2015-05-06 | 山东世纪春食品有限公司 | Production method of special dietary food for diabetes patients for eating |
-
2017
- 2017-12-27 CN CN201711447314.6A patent/CN109965290B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1545943A (en) * | 2003-11-28 | 2004-11-17 | 南宁领标生物技术有限责任公司 | Processing technique for compound product of kudzu root and bitter gourd |
| CN102697060A (en) * | 2012-05-23 | 2012-10-03 | 广东省农业科学院农业生物技术研究所 | Bitter-gourd nutritious food with auxiliary hypoglycemic effect and preparation method thereof |
| CN103830496A (en) * | 2014-02-28 | 2014-06-04 | 廊坊市思科农业技术有限公司 | Blood glucose reduction resistant composition |
| CN104585746A (en) * | 2014-12-23 | 2015-05-06 | 山东世纪春食品有限公司 | Production method of special dietary food for diabetes patients for eating |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111213877A (en) * | 2020-01-21 | 2020-06-02 | 天津天福康生物科技有限公司 | Meal replacement powder with function of regulating organism metabolism and preparation method thereof |
| CN112841533A (en) * | 2021-02-01 | 2021-05-28 | 四川斯力健农业科技有限公司 | Weight-losing meal replacement composition and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN109965290B (en) | 2023-06-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102149348B1 (en) | Pharmaceutical composition comprising chardonnay seed products | |
| CN106619743A (en) | Probiotic solid drink with hypoglycaemic effect and preparation method of probiotic solid drink | |
| CN108112996A (en) | A kind of alimentation composition for controlling diabetes B crowd hyperglycaemia and improving immunity | |
| CN109770361A (en) | A kind of navy bean diet fiber composition and its application | |
| US9737577B2 (en) | Lactic acid bacterium-containing preparation | |
| CN106174585A (en) | Hypoglycemic compositions and hypoglycemic compound probiotic spy's dietary seafood | |
| CN102406860A (en) | Composition for preventing and treating diabetes, and preparation method and use thereof | |
| CN102113648A (en) | Special dietary noodle applicable to people suffering from 'five-high' metabolic syndrome and preparation method thereof | |
| CN102791849A (en) | Lactic acid bacterium-containing preparation | |
| CN110623182A (en) | Probiotic plant solid beverage for treating hyperuricemia and gout | |
| GB2529962A (en) | Multi-functional composition and preparation method and application thereof | |
| CN103284038B (en) | Hyperglycemic composition and preparation method thereof | |
| CN108283285A (en) | A kind of health-care physiotherapeutic food of diabetes | |
| CN102113652A (en) | Special dietary extruded rice applicable to patients suffering from 'five-high' metabolic syndrome and preparation method thereof | |
| CN101766274B (en) | Antioxidant functional food composition containing bamboo-leaves flavones | |
| CA2961465C (en) | Anti-diabetic effects of gypenoside 75 | |
| CN109965290A (en) | Improve intestinal flora meal replacement powder and its application | |
| CN110237117A (en) | A kind of soft capsule and preparation method thereof of Menopause anti-aging | |
| CN112971154A (en) | Solid mixture rich in water-soluble dietary fibers and alpha-amylase inhibitor, and preparation method and application thereof | |
| CN102090637A (en) | Collagen-containing compound nutritious powder | |
| CN108523123A (en) | A kind of full nutritional support food of diabetes | |
| CN107095300A (en) | A kind of biological nutrition compound composition of auxiliary treatment diabetes | |
| JP2019210269A (en) | Composition for treating diabetic disease | |
| CN109549086A (en) | It is a kind of to eat hypoglycemic thick Coarse cereals rice formula more | |
| CN108653298A (en) | Monosaccharide composition, pharmaceutical preparation and its application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |